Introduction
There is a mounting evidence for the presence of oxidative stress in patients undergoing maintenance haemodialysis (MHD) [1] [2] [3] [4] [5] [6] , contributing to poor cardiovascular (CV) and overall outcome [7] . Both increased free radicals production and down-regulated antioxidant enzymes activities contribute to protein, lipid and DNA oxidative damage by-products accumulation in dialysis patients [8] [9] [10] [11] . In addition to the well-established link of oxidative stress with specific causes of renal failure, dialysis procedure and uraemic state, the role of genetic predisposition in enhanced oxidative damage and consequent worsening of MHD patients' prognosis has emerged recently.
Members of the glutathione transferase (GST) enzyme superfamily are able to detoxify accumulated uraemic toxins in MHD patients and posses strong antioxidant activity towards reactive oxygen species (ROS) and peroxides [12 -14] . However, as recently shown by Lin et al. [10] , the capacity to evoke the GST response towards oxidative stress in MHD patients seems to be genetically determined. Namely, almost all members of GST family exhibit genetic polymorphism, resulting in complete lack or lowering of enzyme activity [15] . Approximately half of the population lacks GSTM1 enzyme activity, due to a homozygous deletion of the GSTM1 gene [16] . The GSTM1-null genotype has attracted much attention as a result of risk linkage with lung and bladder cancer [17, 18] and increased susceptibility to coronary heart disease among smokers [19, 20] . Haemodialysis (HD) patients lacking GSTM1 activity exhibit enhanced oxidative DNA damage and higher mortality rate than those with active GSTM1 enzyme [10] . Despite the fact that protein and lipid oxidative modifications have a key role in the pathogenesis of CV complications in these patients, the question of whether the GSTM1 genotype influences the level of protein and lipid oxidative damage by-products in MHD patients has not been well established as yet.
In addition to the GSTM1 polymorphism, GSTT1, GSTP1 and GSTA1 polymorphisms also gained a lot of attention. In the case of GSTT1, gene homozygous deletion present in ∼20% of Caucasians, leads to the lack of GSTT1 enzyme activity [21] . Single-nucleotide polymorphism (SNP) leading to amino acid substitution from isoleucine (Ile) to valine (Val) [22] changes catalytic activity of the GSTP1 enzyme [23] . Thus, if Val is present in GSTP1, specific substrates might accumulate and contribute to oxidative damage [23] [24] [25] . In healthy Caucasians, the frequencies of the genotype variants of GSTP-Ile/Ile, -Ile/Val and -Val/Val are 51.5, 39.4, and 9.1%, respectively [26] . GSTA1 polymorphism is represented by three, apparently linked, SNPs: -567TOG, -69COT and -52GOA. These substitutions result in differential expression with lower transcriptional activation of the variant GSTA1*B (-567G, -69T, -52A) than common GSTA1*A allele (-567T, -69C,-52G) [27] . It seems reasonable to assume that GSTT1-null or GSTA1-or GSTP1-low-activity genotypes might also influence the level of oxidative stress in MHD patients and thus contribute to endogenous predisposition to oxidative damage in the setting of disrupted redox balance. Still, the role of polymorphic expression of GSTA1, GSTP1 and GSTT1 genes in increased oxidant-induced protein and lipid damage among MHD patients has to be established. This has prompted us to assess whether the null or low-activity GSTM1, GSTT1, GSTP1 and GSTA1 genotype alone or in combination correlate with eight biomarkers of oxidative stress, including protein thiol and carbonyl groups, advanced oxidation protein products (AOPP), nitrotyrosine, malondialdehyde (MDA), MDA adducts, total oxidant status (TOS) and pro-oxidant-antioxidant balance (PAB) in HD patients.
Materials and methods

Study subjects
A total of 199 patients (84 male and 115 female, mean age 60.0 ± 12.1 years) undergoing HD treatment for 12-15 h weekly in two dialysis facilities in Belgrade (Center for Renal Diseases, Zvezdara University Medical Center and Department of Nephrology and Hemodialysis, University Teaching Hospital Zemun) were included in this case-control study. All patients were stable, aged over 21 and with HD vintage >3 months before the study. Exclusion criteria were malignancy or infectious co-morbidity based on C-reactive protein values. Patients did not receive any antioxidant therapy (vitamin C or E), while 35.2% of patients received angiotensin-converting inhibitors therapy and 15.1% received statins.
The causes of end-stage renal disease (ESRD) were hypertensive nephrosclerosis (n = 93), glomerulonephritis (n = 32), diabetic nephropathy (n = 25), polycystic renal disease (n = 19), pyelonephritis (n = 19), Balkan endemic nephropathy (n = 7) and obstructive nephropathy (n = 4). Patients were treated with single-use dialysers equipped with low-and high-flux polysulphone membranes, with a membrane surface area of 1.3-2.1. m². A total of 199 controls (85 male and 114 female, mean age 59.3 ± 10.9 years) were recruited from individuals with nephrolithiasis and normal renal function who were admitted to the same hospitals during the same time period. All the participants provided written informed consent. This study protocol was approved by the Institutional Review Board, and the research was carried out in compliance with the Helsinki Declaration (as revised in 2000).
GST genotyping
Genomic DNA was isolated from whole blood using the QIAGEN QIAmp kit (Qiagen, Inc., Chatsworth, CA).
GSTA1 C-69T polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) by Ping et al. [28] . The primers used were GSTA1 C-69T forward: 5′-TGTTGATTGTTTGCCTGAAATT-3′ and GSTA1 C-69T reverse: 5′-GTTAAACGCTGTCACCCGTCCT-3′. The presence of restriction site resulting in two fragments (385 and 96 bp) indicated mutant allele (T/T) and if C/T polymorphism incurred, it resulted in one more fragment of 481 bp ( Figure 1A) .
GSTM1 genotyping was performed by multiplex PCR [29] . Primers used were GSTM1 forward: 5′-GAACTCCCTGAAAAGCTAAAGC-3′ and GSTM1 reverse: 5′-GTTGGGCTCAAATATACGGTGG-3′. Exon 7 of the CYP1A1 gene was co-amplified and used as an internal control using the following primers: CYP1A1 forward: 5′-GAACTGCCACTT CAGCTGTCT-3′ and CYP1A1 reverse: 5′-CAGCTGCATTTG GAAGTGCTC-3′. The presence of the GSTM1-active genotype was detected by the band at 215 bp, since the assay does not distinguish heterozygous or homozygous wild-type genotypes ( Figure 1B) . GSTP1 Ile105Val polymorphism was analysed using the PCR-RFLP method by Harries et al. [30] . Primers used were: GSTP1 Ile105Val forward: 5′-ACCCCAGGGCTCTATGGGAA-3′ and GSTP1 Ile105Val reverse: 5′-TGAGGGCACAAGAAGCCCCT-3′. The presence of restriction site resulting in two fragments (91 and 85 bp) indicated mutant allele (Val/Val), while if Ile/Val polymorphism incurred, it resulted in one more fragment of 176 bp ( Figure 1C ).
GSTT1 genotyping was performed by multiplex PCR [29] . Primers used were GSTT1-forward: 5′-TTCCTTACTGGTCCTCACATCTC-3′ and GSTT1-reverse: 5′-TCACGGGATCATGGCCAGCA-3′. The assay does not distinguish between heterozygous or homozygous wild-type genotypes; therefore, the presence of 480 bp bands was indicative for the GSTT1-active genotype ( Figure 1D ).
Biomarkers of oxidative damage in plasma
Spectrohotometrical analysis was performed for protein thiol groups (method of Jocelyn) [31] , AOPP (modified method of Witko-Sarsat et al.) [5] , MDA (method of Dousset et al.) [32] , TOS (method of Erel) [33] and PAB (method of Alamdari et al.) [34] .
Carbonyl protein derivatives content, MDA protein adducts and nitrotyrosine were measured by enzyme immunoassay (OxiSelectTM ELISA kits, Cell Biolabs).
Statistical analysis
In descriptive statistics, we summarized all continuous variables by means ± standard deviations (SD). Differences in investigated parameters were assessed by using analysis of variance (ANOVA) for continuous variables and χ 2 for categorical variables. The associations between the genotypes and ESRD risk were calculated by using logistic regression to compute odds ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted according to age and gender as potential confounding factors.
In the first step of statistical evaluation of relationships between biomarkers of oxidative damage (SH groups, carbonyls, AOPP, nitrotyrosine, MDA, MDA adducts, TOS, PAB) and combined GSTA1, GSTM1, GSTP1 and GSTT1 genotypes in ESRD patients, distribution was tested by using the Kolmogorov-Smirnov test. For normally distributed data, we performed ANOVA and, if necessary, the Bonferroni post hoc test for locating differences between multiple groups. For data with a non-normal distribution, we used the Mann-Whitney rank-sum test (for between-two-group comparisons) and the Kruskal-Wallis non-parametric test that compared three unpaired groups.
Two-tailed P-values of <0.05 were considered significant. Data were analysed using the Statistical Package for the Social Sciences (SPSS) (version 17.0, Chicago, IL).
Results
Baseline patients' characteristics are presented in Table 1 . No significant difference was observed, except for biochemical parameters of renal function.
GST genotypes and ESRD risk
The distribution of GST genotypes in ESRD patients and controls is presented in Table 2 . The frequency of GSTA1, All results are presented as mean ± SD. *P < 0.001.
GSTM1, GSTP1
and GSTT1 null/low-activity genotypes was higher in ESRD patients than in controls. Significant association between the GST genotype and risk of ESRD development was found only for the GSTM1 genotype. Individuals with GSTM1-null were at 1.6-fold higher risk of ESRD development (OR = 1.6, 95% CI = 1.1-2.4, P = 0.024) than individuals carrying the GSTM1-active genotype. When GST genotypes were analysed in combination (Table 3) , the highest risk of ESRD development was obtained in subjects who carried both GSTM1 and GSTT1-null genotypes (OR = 2.0, 95% CI = 1.1-3.7, P = 0.025). Combination of GSTM1-null with the GSTP1-low-activity genotype was also found to be significant (OR = 1.8, 95% CI = 1.0-3.1, P = 0.042). The GSTM1-null/GSTA1-lowactivity combination had certain effect on ESRD risk (OR = 1.8; 95% CI = 0.9-3.3, P = 0.058).
Association between GST genotype and biomarkers of oxidative damage
The degree of oxidative and nitrosative protein damage in ESRD patients stratified according to GST genotypes is presented in Figure 2 . Plasma protein thiol groups concentration was significantly lower in patients with both GSTM1 or GSTT1-null, as well as, GSTP1-low-activity genotype in comparison to corresponding active genotype (P = 0.001, 0.002 and 0.042, respectively) ( Figure 2A ). Significantly higher plasma carbonyl groups levels were found in patients with low-activity GSTA1-TT or GSTM1-null genotype (P = 0.007 and 0.005, respectively) ( Figure 2B ). AOPP concentrations were increased in patients carrying the GSTM1-or GSTT1-null genotype (P = 0.001 and 0.037, respectively) ( Figure 2C ). As presented, the most pronounced effect regarding protein oxidative damage was observed for the GSTM1 genotype ( Figure 2) . Furthermore, nitrotyrosine, a reliable marker of nitrosative damage of proteins, was found to be higher in patients with the GSTP1-low-activity genotype (P = 0.07) ( Figure 2D ). MDA, a commonly used biomarker of lipid oxidative damage, exists both as free and bound to proteins, nucleic acids and lipoproteins which are designated as MDA adducts. Both free and MDA adduct levels were significantly increased in patients with GST null/low-activity genotypes (Figure 3 ).
Since the effects of different oxidant molecules are additive, we determined the TOS and PAB. Similar to previous results, patients with GST null or low-activity genotypes had increased plasma TOS and PAB levels, with the GSTM1-null genotype carriers having the highest levels (P = 0.001) ( Figure 4A ). Increased TOS and PAB concentrations were also found in patients with GSTT1-null genotype, but did not reach statistical significance.
To assess whether the effects of null/low-activity GST genotypes are more pronounced when combined, we compared the level of oxidative damage between ESRD patients stratified according to the various combinations of GST gene variants ( Table 4 ). The level of oxidative damage of proteins and lipids was lowest in patients with both GSTSM1-and GSTT1-active genotypes, then gradually increased in GSTM1-active/GSTT1-null and GSTM1-null/GSTT1-active ESRD patients, reaching the highest values in patients with both GSTM1-and GSTT1-null genotypes ( Table 4 ). The observed effect was even more obvious if patients were stratified according to the combination of three GST genotypes (Table 4) . Furthermore, when a combination of all four GST genotypes tested was analysed, we found striking evidence in favour of increased susceptibility to lipid peroxidation and protein oxidative and nitrosative damage in ESRD patients carrying combined GSTM1/GSTT-null and low-activity GSTA1 and GSTP1 genotypes (Table 4) . On the other hand, carriers of combined active GSTM1, GSTT1, GSTP1 and GSTT1 genotypes had the lowest level of oxidative stress among ESRD patients.
Discussion
High levels of free radicals that occur in the course of chronic renal failure (CRF) are associated with the disease pathogenesis, its progression and complications [11, 35] . Based on this premise, we speculated that variations in detoxifying and antioxidant activities of GST modulate individual tendency towards ESRD development, regardless of its specific cause. Among four common GST polymorphisms analysed in this study, only the GSTM1-null genotype has shown a significant association with ESRD that was more pronounced if any of the other three null/ low-activity GST genotypes was also present. Our results on the association between GSTM1-null genotype and increased risk of ESRD development are in accordance with several studies performed in Indian population [36] [37] [38] . However, such association was not found among Taiwan Chinese [39] , population of Taipei [10] and Asian Indians ESRD patients [40] . With regard to the GSTT1-null genotype, two studies revealed that the GSTT1-null genotype influences higher risk for ESRD development [37, 39] . The role of low-activity GSTP1-Val/Val Statistically significant difference when compared with the reference group. Fig. 2 . Protein oxidative damage biomarkers in relation to the GST genotype in ESRD patients. Plasma thiol groups decreased in patients with null/ low-activity GST genotype (A). Carbonyl groups, AOPP and nitrotyrosine content in plasma increased in patients with null/low-activity GST genotype (B-D, respectively). *P < 0.05, **P < 0.01. polymorphism was addressed in only two studies [36, 40] , in which it was also associated with increased ESRD risk. Taken together, these data suggest the existence of ethnic-specific GST genetic susceptibility to ESRD development. To our knowledge, this is the first investigation that addressed the susceptibility to ESRD in European Caucasians in association to common GST polymorphisms. Our data on combined effect of various GST genotypes on ESRD development are in accordance with previous investigations of GSTM1/GSTT1 [37] and GSTM1/T1/P1 [36] genotype combinations in Northern Indian patients, although the magnitude of this association was lower in our population. Differential susceptibility to ESRD in various populations might not only be the consequence of differences in the genetic distribution of GSTs among ethnic groups, but also due to the different aetiology of ESRD in various regions. Since ESRD among our patients had distinct aetiology and could hardly be associated with environmental agents metabolized by GST enzymes, except for Balkan endemic nephropathy, weak association obtained for GSTM1-null and its absence with other GST forms is not unexpected. It is reasonable to assume that GST polymorphic expression may be much more important in the course of CRF progression, since accumulated end-products of endogenous and exogenous origin and ROS in these patients act as GST substrates [41] . This is a situation in which gene interaction with disease-specific mechanisms influences further course of disease. The assumption that lack or low-activity GST gene variants contribute to increased susceptibility to oxidative and carbonyl stress in ESRD has been confirmed in the next phase of this investigation, in which the influence of polymorphic GSTA1, GSTM1, GSTP1 and GSTT1 genes was analysed with respect to oxidative phenotype. Oxidative stress in ESRD has multifactorial origin, including low molecular weight uraemic toxins, elevated homocysteine level, increased carbonyl stress, with decreased expression of extracellular glutathione peroxidase produced by renal parenchymal cells, as well as, exacerbations of oxidative stress by dialysis sessions and severe chronic inflammation [11, 35, 42] . Oxidative stress in ESRD patients is considered the cornerstone of atherosclerotic process. Carotid artery intima-media thickness in Fig. 3 . Lipid oxidative damage biomarkers in relation to the GST genotype in ESRD patients. Plasma MDA concentrations and MDA adducts content increased in patients with null/low-activity GST genotype (A and B, respectively). *P < 0.05, **P < 0.01. chronic HD patients correlates with lipid peroxidation byproducts [43] , while serum MDA is a strong predictor of prevalent cardiovascular disease in these patients [44] . Besides, the content of AOPP independently predicts atherosclerotic CV events in non-diabetic pre-dialysis patients [45] . It is important to note that GST family members play a dual role in defence mechanisms that counteract complex biochemical changes present in uraemic state. Namely, all products of analysed GST genes possess both glutathione conjugating and antioxidant enzymatic activity [18, 46] . According to the results presented in this study, the level of protection against both oxidative and carbonyl stress in uraemic syndrome is influenced by common GST polymorphisms which determine the quantity and/or activity of GST protein 'echelons' that act upon organic hydroperoxides and accumulated harmful compounds.
The data concerning genetic predisposition to worse oxidative phenotype in patients with CRF are limited. Lin et al. [10] showed that HD patients with the GSTM1-null genotype are more vulnerable to oxidative DNA damage and are at greater risk for death compared with those who possess active GSTM1 genotype. In this study, we addressed the most relevant classes of oxidative protein and lipid damage by-products encountered in ESRD, as well as, TOS and PAB in relation to GSTA1, GSTM1, GSTP1 and GSTT1 genotypes. We found that individual GST polymorphisms influence vulnerability to both protein and lipid oxidation, with GSTM1-null gene variant having the most pronounced effect. Besides, our results have shown a strong combined effect of null or low-activity GSTM1, GSTT1, GSTA1 and GSTP1 genotypes in terms of susceptibility towards oxidative and carbonyl stress in patients with ESRD. Our results confirmed similar findings presented in patients with benign prostate hyperplasia in which combined GSTM1-null/GSTT1-null genotype was associated with increased plasma MDA level [47] . Our study is also consistent with the results of Tang et al. [48] , who showed that coronary artery disease patients with the GSTM1-null/GSTT1-null genotype have lower total antioxidant capacity than those with both active genotypes [48] . Besides, this genotype combination was Fig. 4 . TOS and PAB in relation to the GST genotype in ESRD patients. TOS and PAB values increased in patients with null/low-activity GST genotype (A and B, respectively). *P < 0.05, **P < 0.01. associated with enhanced DNA damage in many studies that investigated the role of GST polymorphisms in relation to cancer risk [49] [50] [51] [52] . In the light of the role that GST enzymes have in detoxification and as antioxidant enzymes, results of this and other studies on association between null/low-activity GSTM1, GSTT1, GSTP1 and GSTA1 genotypes and increased oxidant damage of proteins and lipids are biologically plausible. According to the presence of various GST gene variants in combination, ESRD patients may be stratified in terms of level of oxidative, carbonyl stress and nitrosative stress. Concerning the latter, imbalance in the relative levels of SOD and GPX, already observed in HD patients [8, 9, 13] , influences the ratio of nitric oxide: superoxide anion leading to an increase in peroxynitrite production [53] . Although the association between GST null or lowactivity gene variants and plasma nitrotyrosine level in ESRD patients was relatively mild, our findings suggest that their antioxidant activities at least partially affect the level of nitrosative damage. Since oxidative stress parameters correlate with CV complications and mortality [10, 45, 54, 55] , it may be speculated that interaction between the uraemic state and combined GST genotype would represent at least one of the potential mechanisms explaining inter-individual differences in terms of CV outcome in these patients. Certain limitations might be considered in our study. The case-control design was used for estimation of associations between GST genotypes and ESRD development, and therefore, selection bias might influence the results. Our control group was hospital-based, thus the use of population controls may have been more appropriate. The cross-sectional design performed for analyses of influence of GST genotypes on by-products of oxidative stress did not allow us to investigate the role of GST polymorphisms in the development of CV complications in ESRD patients. Nevertheless, this study may offer some essential information that could be the base for future longitudinal research. In addition to prognosis, our results may have implications in new approaches to the antioxidant therapy in HD patients. The suggested therapeutic interventions aimed at reducing oxidative stress in HD patients include biocompatible membranes, administration of antioxidants and substances indirectly affecting oxidative stress [11] . Recently, vitamin E-bonded membranes for haemodialysers have been developed, which have a wide spectrum of positive effects on antioxidant status in dialysis patients [56] [57] [58] . The results obtained in this study suggest that the use of dialysers with vitamin E-bonded membranes would be of most benefit for patients with combined GST null or low-activity genotypes. Besides, the GST genotype determination in HD patients could be a step forward to individualization of antioxidant administration. In their recent review, Coumbes and Faset reported findings of more than 50 studies in which the effects of antioxidant therapy were investigated in HD patients. Only α-tocopherol and N-acetylcysteine treatment consistently decreased oxidative stress. Besides, the authors indicated that future studies need first to develop valid oxidative stress biomarkers before evaluating the efficiency of antioxidant therapy [59] . Since susceptibility to oxidative damage differs with respect to the GST genotype, it seems reasonable to assume that individuals' GST 'genetic profile', in addition to plausible oxidative stress biomarkers, should be also considered in the optimization of form, dose and time course of antioxidant treatment.
Based on the results of this investigation, it may be concluded that the GSTM1-null genotype is associated with increased risk of ESRD development and enhanced susceptibility to oxidative stress in dialysis patients. The presence of GSTT1-null or GSTP1-low-activity (Val/Val and Ile/Val) genotypes in ESRD patients also significantly influences the level of oxidative damage by-products, but not as much as GSTM1-null. However, the effect modification with regard to oxidative phenotype in HD patients is most pronounced if GSTM1-and GSTT1-null as well as low-activity GSTA1 and GSTP1 genotypes are present in combination. Taken together, these results suggest a possibility for GST genotype-based stratification of ESRD patients which could improve the attempts towards individualization of antioxidant treatment.
